Pancreatic cystic lesions require risk-stratified management that balances malignant potential against operative morbidity, surveillance burden, and competing patient-level risk. --- ### Clinical Framework > [!abstract] Clinical Key > The central task is identifying the minority of cystic lesions with biologically meaningful risk. Management integrates: - cyst phenotype - ductal anatomy - mural nodularity / solid component - interval change - symptoms - cytology / molecular data when available - operative candidacy - competing life expectancy > **Longitudinal change often matters more than the index cyst measurement.** --- ### Cystic Lesion Spectrum #### Mucinous Neoplasms - [[Intraductal Papillary Mucinous Neoplasm (IPMN)]] - [[Mucinous Cystic Neoplasm (MCN)]] #### Non-Mucinous Neoplasms - [[SCN]] - [[Solid pseudopapillary neoplasms (SPNs)]] - [[Cystic PanNET]] #### Inflammatory Collections - [[Pancreatitis-Associated Collections]] #### Rare Lesions - [[Lymphoepithelial Cyst]] - [[Duplication Cyst]] --- ### Diagnostic Evaluation Initial characterization is driven by high-quality MRI/MRCP and pancreas protocol CT. EUS is selectively incorporated for indeterminate morphology, mural nodularity, ductal uncertainty, or fluid/cytology acquisition. Key features: - duct communication - main duct dilation - mural nodule / solid component - cyst growth - multifocality - pancreatic atrophy - calcification - pancreatitis history Related: - [[Cyst Fluid Analysis]] - [[Pancreatic MRI]] - [[Pancreas Protocol CT]] - [[EUS]] --- ### Risk Stratification Formal risk frameworks are most relevant for IPMN-spectrum disease, but the principles apply broadly to mucinous cyst management. High-risk concern is driven by: - obstructive jaundice - enhancing mural nodule / solid component - significant main duct dilation - suspicious or positive cytology - interval progression - elevated CA 19-9 - recurrent pancreatitis attributable to the lesion Size modifies risk but should not be interpreted in isolation. --- ### Guideline Frameworks Guideline variation is most relevant for IPMN, particularly around operative thresholds, surveillance intervals, and surveillance cessation. Related: - [[Intraductal Papillary Mucinous Neoplasm (IPMN)]] - [[Pancreatic Cyst Surveillance]] --- ### Surveillance Principles > [!important] Management Principle > Surveillance should only be continued in patients who remain acceptable operative candidates. MRI/MRCP is the dominant surveillance modality. EUS is selectively added for interval change, concerning morphology, or diagnostic uncertainty. Surveillance intensity should reflect: - cyst phenotype - ductal evolution - interval growth - mural nodularity - patient age/frailty - willingness and candidacy for surgery --- ### Operative Management Resection is appropriate when estimated biological risk outweighs pancreatic operative morbidity. Operative decision-making depends on: - lesion phenotype - location - duct involvement - cytology - patient physiology - expected endocrine/exocrine consequences - remnant surveillance implications Common operations: - [[Pancreaticoduodenectomy]] - [[Distal Pancreatectomy]] - [[Total Pancreatectomy]] - [[Enucleation]] --- ### Challenging Scenarios #### Multifocal Branch-Duct IPMN Usually managed by dominant lesion biology rather than attempting complete radiographic clearance. #### Elderly or Frail Patients Operative benefit narrows as competing mortality and surgical morbidity rise. #### Incidental Subcentimeter Cysts Common, often indolent, and frequently over-surveilled. #### Pancreatitis-Associated Cystic Lesions Inflammatory collections should not be assumed without a convincing pancreatitis history. #### Hereditary Risk Requires individualized management within a high-risk pancreas surveillance framework. --- ### Practical Management Approach 1. Define cyst phenotype 2. Determine mucinous vs non-mucinous lineage 3. Assess ductal involvement 4. Identify high-risk morphology 5. Use EUS/fluid analysis only if it changes management 6. Assess operative candidacy 7. Balance malignant risk against pancreatic morbidity 8. Choose surveillance, intensified evaluation, or resection --- ### Related Pages - [[Intraductal Papillary Mucinous Neoplasm (IPMN)]] - [[Mucinous Cystic Neoplasm (MCN)]] - [[SCN]] - [[Pancreatic MRI]] - [[EUS]] - [[Cyst Fluid Analysis]] - [[Pancreaticoduodenectomy]] - [[Postoperative Pancreatic Fistula]]